Investigation of Endocrine Disease Frequency in Dyslipidemia
Yıl: 2023 Cilt: 5 Sayı: 1 Sayfa Aralığı: 185 - 193 Metin Dili: İngilizce DOI: 10.5152/ABCR.2023.223353 İndeks Tarihi: 04-06-2023
Investigation of Endocrine Disease Frequency in Dyslipidemia
Öz: Objective: The purpose of our research was to investigate the frequency of endocrine disorders like diabetes, high blood pres- sure, obesity, hyperuricemia, insulin resistance, and thyroid dys- function, all of which are thought to be critical in the process of diagnosing and treating patients who have dyslipidemia. Methods: Between December 2010 and May 2012, a total of 200 patients with dyslipidemia and 23 healthy control groups without dyslipidemia who applied to the general internal medi- cine and subspecialty outpatient clinics at the Atatürk University Faculty of Medicine were included in the study. The mean age of the dyslipidemic patients was 49 ± 15 years, and the mean age of the healthy control groups was 32 ± 17 years. Anthropometric measures were obtained, as well as measurements of triglycer- ide levels, total cholesterol levels, low-density lipoprotein cho- lesterol levels, high-density lipoprotein cholesterol levels, free T4 levels, Thyroid-stimulating hormone (TSH), The hemoglobin A1c (HbA1C) levels, serum uric acid levels, fasting insulin levels, fasting blood glucose levels and Hemoglobin A1c (HbA1c) . Results: It was shown that diabetes mellitus is the most common endocrine condition that occurs in conjunction with dyslipidemia, with a prevalence of 52%. While there was a statistically signifi- cant increase in HbA1c, body mass index, and uric acid values of the dyslipidemic group compared to the control group (P < .05), no difference was found between the 2 groups in TSH and homeo- stasis model assessment index-insulin resistance (HOMA-IR) val- ues. Also, 85 of the patients in the dyslipidemic group (42.5%) were found to have systemic hypertension, but only one of the patients in the control group (4.3%) had hypertension (p < .001). Conclusion: The frequency of diabetes, hypertension, obesity, and hyperuricemia in patients with dyslipidemia was signifi- cantly higher than in the control group. Considering these dis- eases when treating dyslipidemia is important for cardiovascular morbidity and mortality.
Anahtar Kelime: Dislipidemide Endokrin Hastalık Sıklığının Araştırılması
Öz: Amaç: Çalışmamızda dislipidemi saptanan hastalarda tanı ve tedavi yönetiminde önemli olduğunu düşündüğümüz diabet, hipertansiyon, obezite, hiperürisemi, insülin direnci ve tiroid fonksiyon bozukluğu gibi endokrin hastalıkların sıklıklarının ince- lenmesi amaçlanmıştır. Yöntemler: Çalışmaya 2010 Aralık-2012 Mayıs ayları arasında Atatürk Üniversitesi Tıp Fakültesi Genel Dahiliye ve yandal polikliniklerine başvuran yaş ortalaması 49 ±15 yıl olan dislipid- emik 200 hasta ile dislipidemisi olmayan yaş ortalaması 32 ± 17 yıl olan 23 sağlıklı kontrol grubu alındı. Antropometrik ölçümlere bakıldı, total kolesterol, trigliserid, LDL (low-density lipoprotein) kolesterol, HDL (high-density lipoprotein) kolesterol, serbest T4, TSH (Tiroid Stimülan Hormon), serum ürik asit, açlık insülin, açlık kan glukozu ve HBA1c (Hemoglobin A1c) düzeyi çalışıldı. Bulgular: Dislipidemiye eşlik eden endokrin hastalıkların başında %52 oranla diabetes mellitus’un olduğu saptandı. Dislipidemik grubunun HbA1C, VKİ (vücut kitle indeksi) ve serum ürik asid değerlerinde kontrol grubuna göre istatistiksel olarak anlamlı yükseklik saptanırken (p < .05), TSH ve HOMA-IR (homeosta- sis model assessment index) değerlerinde iki grup arasında fark saptanmadı. Ayrıca dislipidemik grupta 85 (%42,5) hastada sistemik hipertansiyon saptanırken kontrol grubunda hipertan- siyonu olan 1 hasta (%4,3) tesbit edildi (p < .001). Sonuç: Dislipidemili hastalarda diabet, hipertansiyon, obezite ve hiperürisemi sıklığı kontrol grubuna göre anlamlı olarak yük- sek saptandı. Dislipidemi tedavi edilirken bu hastalıkların göz önünde bulundurulması kardiyovasküler morbidite ve mortalite için önemlidir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18(10):689-700. [CrossRef]
- 2. Castro Cabezas MC, Burggraaf B, Klop B. Dyslipidemias in clinical practice. Clin Chim Acta. 2018;487:117-125. [CrossRef]
- 3. Zhu J, Zhang Y, Wu Y, et al. Obesity and dyslipidemia in Chi- nese adults: A cross-sectional study in Shanghai, China. Nutrients. 2022;14(11):2321. [CrossRef]
- 4. Charoensri S, Turnsaket S, Pongchaiyakul C. Hypertriglyc- eridemia as an independent predictor for ten-year incidence of diabetes in Thais. Vasc Health Risk Manag. 2021;17: 519-525. [CrossRef]
- 5. Katsimardou A, Imprialos K, Stavropoulos K, Sachinidis A, Dou- mas M, Athyros V. Hypertension in metabolic syndrome: novel insights. Curr Hypertens Rev. 2020;16(1):12-18. [CrossRef]
- 6. Borghi C, Fogacci F, Agnoletti D, Cicero AFG. Hypertension and dyslipidemia combined therapeutic approaches. High Blood Press Cardiovasc Prev. 2022;29(3):221-230.[CrossRef]
- 7. Braga F, Pasqualetti S, Ferraro S, Panteghini M. Hyperurice- mia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis. Clin Chem Lab Med. 2016;54(1):7-15. [CrossRef]
- 8. Bayram F, Kocer D, Gundogan K, et al. Prevalence of dyslipi- demia and associated risk factors in Turkish adults. J Clin Lipidol. 2014;8(2):206-216. [CrossRef]
- 9. Kayıkçıoğlu M, Tokgözoğlu L, Kılıçkap M, et al. Data on prevalence of dyslipidemia and lipid values in Turkey: sys- tematic review and meta-analysis of epidemiological stud- ies on cardiovascular risk factors. Turk Kardiyol Dern Ars Turk Kardiyol Derneginin Yayin Organidir. 2018;46(7): 556-574.
- 10. Akçay G, Akçay MN, Orbak R. Ansiklopedik sözlük İlaveli Endokrinoloji ve Metabolizma Hastalıkları. Ankara: Aktif Yayınevi. 2012:335-349.
- 11. Ascaso JF, Millán J, Mateo-Gallego R, et al. Prevalence of metabolic syndrome and cardiovascular disease in a hyper- triglyceridemic population. Eur J Intern Med. 2011;22(2): 177-181. [CrossRef]
- 12. Vodnala D,Rubenfire M ,Brook RD. Secondary causes of dys- lipidemia. Am J Cardiol. 2012;110(6):823-825. [CrossRef]
- 13. Al-Meshaweh AF, Jafar Y, Asem M, Akanji AO. Determinants of blood uric acid levels in a dyslipidemic Arab population. Med Princ Pract. 2012;21(3):209-216. [CrossRef]
- 14. Pitso L, Mofokeng TRP, Nel R. Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central South Africa. BMC Endocr Disord. 2021;21(1):159. [CrossRef]
- 15. de Oliveira EP, Burini RC. High plasma uric acid concentra- tion: causes and Consequences. Diabetol Metab Syndr. 2012;4:12). [CrossRef]
- 16. Feng X, Guo Y, Tu H, et al. Temporal changes in serum uric acid and risk for metabolic syndrome: a longitudinal cohort study. Diabetol Metab Syndr. 2022;14(1):92. [CrossRef]
- 17. Peng TC, Wang CC, Kao TW, et al. ABD’li yetişkinlerde hiperürisemi ve lipid profilleri arasındaki ilişki. Biomed Arş. 2015;2015:127596.
- 18. Liu F, Du GL, Song N, et al. Hyperuricemia and its association with adiposity and dyslipidemia in Northwest China: results from cardiovascular risk survey in Xinjiang (CRS 2008- 2012). Lipids Health Dis. 2020;19(1):58. [CrossRef]
- 19. Bayram, DİLARA, Aydın V, et al. Investigation of drug use in essential hypertension patients with or without cardio- vascular comorbidity. Dokuz Eylül Univ Tıp Fak Derg. 2020;34(2):117-130.
- 20. Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spaso jevic-Kalimanovska V. Obesity and dyslipidemia. Metabo- lism. 2019;92:71-81. [CrossRef]
- 21. Malik SUF, Mahmud Z, Alam J, Islam MS, Azad AK. Relation- ship among obesity, blood lipids and insulin resistance in Bangladeshi adults. Diabetes Metab Syndr. 2019;13(1): 444-449. [CrossRef]
- 22. Badoud F, Perreault M, Zulyniak MA, Mutch DM. Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals. FASEB J. 2015;29(3):748-758. [CrossRef]
- 23. Su X, Chen X, Wang B. Pathology of metab olically-related dyslipidemia. Clin Chim Acta. 2021;521:107-115. [CrossRef]
- 24. Ipsen DH, Tveden-Nyborg P, Lykkesfeldt J. Dyslipidemia: obese or not obese—that is not the question. Curr Obes Rep. 2016;5(4):405-412. [CrossRef]
- 25. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014;371(12): 1131-1141. [CrossRef]
- 26. Paramsothy P, Knopp R, Bertoni AG, Tsai MY, Rue T, Heck- bert SR. Combined hyperlipidemia in relation to race/ ethnicity, obesity, and insulin resistance in the multi-ethnic study of atherosclerosis. Metabolism. 2009;58(2):212-219. [CrossRef]
- 27. Nasreddine L, Naja F, Tabet M, et al. Obesity is associated with insulin resistance and components of the metabolic syndrome in Lebanese adolescents. Ann Hum Biol. 2012; 39(2):122-128. [CrossRef]
- 28. Burguete-García AI, Ramírez Valverde AG, Espinoza- León M, et al. Severe quantitative scale of acanthosis nigri- cans in neck is associated with abdominal obesity, HOMA-IR, and hyperlipidemia in obese children from Mexico City: a cross-sectional study. Dermatol Res Pract. 2022;2022: 2906189. [CrossRef]
- 29. Sala-Vila A, Cofán M,Mateo-Gallego R, et al. Inverse associa- tion between serum phospholipid oleic acid and insulin resistance in subjects with primary dyslipidaemia. Clin Nutr. 2011;30(5):590-592. [CrossRef]
- 30. de Siqueira, A. C. G., Cotrim, H. P., Rocha, R., Carvalho, F. M., de Freitas, L. A., Barreto, D., ... & Landeiro, L. (2005). Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. European journal of gastroenterology & hepatology, 17(8), 837-841.
- 31. Acg S, Cotrim Hp, Rocha R, et al. Nonalcoholic Fatty Liver Disease And Insulin Resistance: İmportance of Risk Factors And Histological Spectrum. Eur J Gastroenterol Hepatol. 2005;17:837-841.
- 32. Abdel-Gayoum AA. Dyslipidemia and serum mineral profiles in patients with thyroid disorders. Saudi Med J. 2014;35(12): 1469-1476.
- 33. Zhang X, Song Y, Feng M, et al. Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation via AMP- activated protein kinase in the liver. J Lipid Res. 2015;56(5):963-971. [CrossRef]
- 34. Pesic MM, Radojkovic D, Antic S, Kocic R, Stankovic- Djordjevic D. Subclinical hypothyroidism: association with cardiovascular risk factors and components of metabolic syndrome. Biotechnol Biotechnol Equip. 2015;29(1): 157-163. [CrossRef]
- 35. Deng B, Yuan Y, Zhong M, Ren R, Deng W, Duan X. The rela- tionship between metabolic parameters, age, and thyroid status: A cross-sectional study-based national survey of iodine nutrition, thyroid disease. Risk Manag Healthc Policy. 2021;14:1723-1730. [CrossRef]
| APA | Aslan V, AKÇAY G (2023). Investigation of Endocrine Disease Frequency in Dyslipidemia. , 185 - 193. 10.5152/ABCR.2023.223353 |
| Chicago | Aslan Volkan,AKÇAY GÜNGOR Investigation of Endocrine Disease Frequency in Dyslipidemia. (2023): 185 - 193. 10.5152/ABCR.2023.223353 |
| MLA | Aslan Volkan,AKÇAY GÜNGOR Investigation of Endocrine Disease Frequency in Dyslipidemia. , 2023, ss.185 - 193. 10.5152/ABCR.2023.223353 |
| AMA | Aslan V,AKÇAY G Investigation of Endocrine Disease Frequency in Dyslipidemia. . 2023; 185 - 193. 10.5152/ABCR.2023.223353 |
| Vancouver | Aslan V,AKÇAY G Investigation of Endocrine Disease Frequency in Dyslipidemia. . 2023; 185 - 193. 10.5152/ABCR.2023.223353 |
| IEEE | Aslan V,AKÇAY G "Investigation of Endocrine Disease Frequency in Dyslipidemia." , ss.185 - 193, 2023. 10.5152/ABCR.2023.223353 |
| ISNAD | Aslan, Volkan - AKÇAY, GÜNGOR. "Investigation of Endocrine Disease Frequency in Dyslipidemia". (2023), 185-193. https://doi.org/10.5152/ABCR.2023.223353 |
| APA | Aslan V, AKÇAY G (2023). Investigation of Endocrine Disease Frequency in Dyslipidemia. Archives of Basic and Clinical Research, 5(1), 185 - 193. 10.5152/ABCR.2023.223353 |
| Chicago | Aslan Volkan,AKÇAY GÜNGOR Investigation of Endocrine Disease Frequency in Dyslipidemia. Archives of Basic and Clinical Research 5, no.1 (2023): 185 - 193. 10.5152/ABCR.2023.223353 |
| MLA | Aslan Volkan,AKÇAY GÜNGOR Investigation of Endocrine Disease Frequency in Dyslipidemia. Archives of Basic and Clinical Research, vol.5, no.1, 2023, ss.185 - 193. 10.5152/ABCR.2023.223353 |
| AMA | Aslan V,AKÇAY G Investigation of Endocrine Disease Frequency in Dyslipidemia. Archives of Basic and Clinical Research. 2023; 5(1): 185 - 193. 10.5152/ABCR.2023.223353 |
| Vancouver | Aslan V,AKÇAY G Investigation of Endocrine Disease Frequency in Dyslipidemia. Archives of Basic and Clinical Research. 2023; 5(1): 185 - 193. 10.5152/ABCR.2023.223353 |
| IEEE | Aslan V,AKÇAY G "Investigation of Endocrine Disease Frequency in Dyslipidemia." Archives of Basic and Clinical Research, 5, ss.185 - 193, 2023. 10.5152/ABCR.2023.223353 |
| ISNAD | Aslan, Volkan - AKÇAY, GÜNGOR. "Investigation of Endocrine Disease Frequency in Dyslipidemia". Archives of Basic and Clinical Research 5/1 (2023), 185-193. https://doi.org/10.5152/ABCR.2023.223353 |
